Abstract: The present invention relates to methods of determining the presence or absence of certain cancers in a human individual, as well as to related methods to determine the response to therapy against certain cancers in a human individual, in particular ovarian cancer in a woman. Such methods are based on the detection-from (eg cell-free) DNA of said human individual—of one or more methylated (or un-methylated) CpGs being associated with differentially methylated regions (DMRs) of the present invention; such as methylation (or un-methylation) at one or more or all of certain CpGs being associated with such DMRs. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detecting or managing certain cancers in women or men, in particular ovarian cancer in women.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
March 5, 2024
Assignees:
Eurofins Genomics Europe Sequencing GMBH, Genedata AG, UCL Business LTD.
Inventors:
Martin Widschwendter, Allison Jones, Iona Evans, Harri Lempiäinen, Johannes Eichner, Tamas Rujan, Timo Wittenberger, Tobias Paprotka, Benjamin Lindner